Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ITCI Intra-Cellular Therapies	$131.87	$131.78	$64.09 ▼ $131.98	$14.05B	0.69	1.50 million shs	N/A
NUVL Nuvalent	$71.00 0.0%	$71.48	$55.54 ▼ $113.51	$5.08B	1.42	486,291 shs	407,857 shs
SMMT Summit Therapeutics	$23.09 +1.5%	$22.38	$2.10 ▼ $36.91	$17.15B	-0.94	3.86 million shs	2.75 million shs
TEVA Teva Pharmaceutical Industries	$16.83 -0.4%	$15.34	$12.47 ▼ $22.80	$19.08B	0.62	9.98 million shs	9.48 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	+3.17%	+97.29%
NUVL Nuvalent	-0.03%	-0.84%	+0.31%	-8.89%	-0.95%
SMMT Summit Therapeutics	+1.49%	-6.33%	-6.21%	+8.05%	+414.25%
TEVA Teva Pharmaceutical Industries	+0.84%	-7.17%	+23.89%	+3.66%	+0.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ITCI Intra-Cellular Therapies	0.6076 of 5 stars	1.1	0.0	0.0	4.5	0.0	1.7	0.6
NUVL Nuvalent	2.634 of 5 stars	3.5	2.0	0.0	0.0	3.5	3.3	0.0
SMMT Summit Therapeutics	2.9407 of 5 stars	4.5	1.0	0.0	0.0	4.0	1.7	0.0
TEVA Teva Pharmaceutical Industries	3.5058 of 5 stars	3.6	5.0	0.8	0.0	3.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
NUVL Nuvalent	2.90	Moderate Buy	$115.50	62.68% Upside
SMMT Summit Therapeutics	3.09	Buy	$37.40	61.97% Upside
TEVA Teva Pharmaceutical Industries	3.13	Buy	$24.43	45.15% Upside

Current Analyst Ratings Breakdown

Latest NUVL, TEVA, SMMT, and ITCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/28/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
4/28/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00 ➝ $40.00
4/28/2025	TEVA Teva Pharmaceutical Industries	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/25/2025	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$31.00 ➝ $44.00
4/23/2025	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/2/2025	ITCI Intra-Cellular Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$132.00 ➝ $132.00
3/26/2025	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$35.00

(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
NUVL Nuvalent	N/A	N/A	N/A	N/A	$10.94 per share	N/A
SMMT Summit Therapeutics	$700K	24,497.37	N/A	N/A	$0.11 per share	209.91
TEVA Teva Pharmaceutical Industries	$16.62B	1.15	$3.33 per share	5.05	$4.75 per share	3.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
NUVL Nuvalent	-$126.22M	-$4.39	N/A	N/A	N/A	N/A	-28.63%	-27.15%	N/A
SMMT Summit Therapeutics	-$614.93M	-$0.34	N/A	N/A	N/A	N/A	-85.42%	-52.66%	N/A
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.40	1.44	-9.91%	42.46%	6.65%	7/30/2025 (Estimated)

Latest NUVL, TEVA, SMMT, and ITCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
2/27/2025	Q4 2024	NUVL Nuvalent	-$1.03	-$1.05	-$0.02	-$1.05	N/A	N/A
2/24/2025	Q4 2024	SMMT Summit Therapeutics	-$0.08	-$0.08	N/A	-$0.08	N/A	$0.20 million
2/21/2025	Q4 2024	ITCI Intra-Cellular Therapies	-$0.08	-$0.16	-$0.08	-$0.16	$205.08 million	$199.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	6.01%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
NUVL Nuvalent	N/A	23.07	23.07
SMMT Summit Therapeutics	N/A	8.31	8.31
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ITCI Intra-Cellular Therapies	92.33%
NUVL Nuvalent	97.26%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ITCI Intra-Cellular Therapies	2.60%
NUVL Nuvalent	12.52%
SMMT Summit Therapeutics	88.30%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
NUVL Nuvalent	40	71.60 million	62.16 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	86.28 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

NUVL, TEVA, SMMT, and ITCI Headlines

Recent News About These Companies

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Deutsche Bank AG

May 16 at 4:35 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd: Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

May 15 at 6:54 PM | finanznachrichten.de

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

May 15 at 6:12 PM | globenewswire.com

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

May 15 at 12:12 PM | finance.yahoo.com

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

May 15 at 12:12 PM | insidermonkey.com

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 58,893 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 15 at 7:56 AM | marketbeat.com

Janus Henderson Group PLC Acquires 1,945,688 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 15 at 5:40 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

May 14 at 12:42 PM | msn.com

JPMorgan Chase & Co. Upgrades Teva Pharmaceutical Industries (NYSE:TEVA) to Overweight

May 14 at 8:24 AM | marketbeat.com

Integral Health Asset Management LLC Buys Shares of 500,000 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 14 at 6:17 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stake Boosted by Graham Capital Management L.P.

May 14 at 5:39 AM | marketbeat.com

Bank of America Corp DE Sells 1,935,982 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 14 at 4:12 AM | marketbeat.com

Iron Triangle Partners LP Has $48.49 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 13 at 8:22 AM | marketbeat.com

First Manhattan CO. LLC. Has $1.36 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 13 at 6:10 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd (TEVA) Surpasses Sustainability Targets in 2024 Healthy ...

May 12, 2025 | gurufocus.com

Teva to lay off an estimated 250-300 employees in Israel

May 11, 2025 | en.globes.co.il

FORA Capital LLC Purchases Shares of 106,078 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 11, 2025 | marketbeat.com

Crestline Management LP Buys Shares of 55,371 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 11, 2025 | marketbeat.com

BNP Paribas Financial Markets Purchases 168,699 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 11, 2025 | marketbeat.com

First Trust Advisors LP Sells 58,194 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 11, 2025 | marketbeat.com

DME Capital Management LP Has $10.33 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVL, TEVA, SMMT, and ITCI Company Descriptions

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Nuvalent NASDAQ:NUVL

$71.00 -0.02 (-0.03%)

As of 05/15/2025 04:00 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Summit Therapeutics NASDAQ:SMMT

$23.09 +0.34 (+1.49%)

As of 05/15/2025 04:00 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$16.83 -0.06 (-0.36%)

As of 05/15/2025 03:53 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time